OSU researchers found compounds that turn the Bcl-2 protein from a cancer cell protector into a tumor killer, offering new treatment possibilities for breast cancer and other cancers. This breakthrough could lead to therapies that specifically target cancer cells, leaving normal cells unharmed. OSU researchers found compounds that turn the Bcl-2 protein into a tumor killer, offering new breast cancer therapies.
Studies showed these compounds effectively kill cancer cells by changing Bcl-2’s shape. Future steps involve advancing to human trials and veterinary uses. Researchers at Oregon State University have identified compounds that transform a protein known for protecting cancer cells into a tumor killer.
Researchers report that their multi-year study paves the way for potential treatments for breast cancer and other cancers that depend on the Bcl-2 protein to resist therapy and develop drug resistance. “The holy grail in cancer research is finding a molecular target that plays a major, essential role in cancer cell growth that you can go after without causing side effects – that is, without affecting regular cells,” said Siva Kolluri, professor of environmental and molecular toxicology in the College of Agricultural Sciences. “Multiple pathways control a normal cell to be normal, and cancer cells hijack one of those pathways that control the rate of proliferation and/or death.
” Mechanisms of Cell Death Many types of cells are recycled, Kolluri said, through a pr.